This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 20| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2268 | LIMK1, CENPE, FZD2, ENO2, ITGA9, COPA, KIAA0660, GTF2H1, VPS41, RGS20, MATK, STOML1, BASP1, EPB42, ALDH3B2, MEL, CAT56, RAB3A, PSCD3, PLD2, ADCYAP1R1, ALDH3B1, RHD, CSF3R, KIAA0063, KIAA0296, LRP6, ENO3, CTRB1, YES1, IncytePD:1404153, GYS1, MDFI, GABRE, IncytePD:2685601, CD3Z, DTYMK, SPTBN2, IncyteP | RNAs | Human | Upregulated in PT than PN (with 3 fold change) | Diagnostic | Metastatic HCC v/s Primary HCC | p < 0.01 | Tissue | 12640447 |
| 2341 | ZNF216 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.54) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2360 | PARD3, INSIG1, MPHOSPH9, SKP2, CUL4B, CETN2, ETS2, USH1C, PTPN11, OASL, ARL5, SMURF2, CDC42SE1, CSNK1G3, RACGAP1, DNAJC10, KCNK1, CDO1, CNGA1, NUDT9, GSTM3, SLC16A5, SARA2, ID2, MTHFD2L, SYNGR2, PRL10A, RNF130, MAFB, FLJ23749, LARP6, R3HDM, ZNF652, PGGT1B, HEXB, SLC27A2, ZBTB38, SH3GLB2, AGPAT3, GCH | RNAs | Human | Differentially expressed between recurrence HCC disease | Prognostic | Recurrent v/s non-recurrent HCC | p < 0.05 | Tissue | 17975138 |
| 2419 | IGF2 | Protein | Human | Upregulated in HCC than normal | Diagnostic | HCC v/s normal | (R2 = 0.85) compared with HCC versus normal liver (R2 = 0.51) | Tissue | 14517841 |
| 2460 | MEF2B | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.49) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2464 | EGR3, MFAP3, EST, MMP9, PDCD4, EST, FLJ37853, ARHE, MAD2L1, NMNAT2, FLJ22016, SND1, MIDORI, FLJ36229, MGST2, CTPS2, OASL, HK2, EEF2, Taxilin, NT5C, CLNS1A, UNC5B, TSC, TNFSF6, KIAA1691, S100A10, ATP6V1D, ASB4, AGR2, KIAA0205, JJAZ1, LOC285859, KIAA0157, PPA2, eIF3k, SGKL, BLMH, ERG-1, BRCA2, PPP2R2A | RNAs | Human | Differentially expressed (14 Upregulated and 49 Downregulated) in treatment responder v/s non-responders | Predictive | treatment responder v/s non-responders | p < 0.01 | Tissue | 15447987 |
| 2484 | SOX6, ITIH4, HDGF, SKIP1, RBP4, LOC92033, UGT2B7, FABP1, GATM, UQCRC1, UK114, CP, PBEF, KAL1, CES2, GPX4, UGT1A4, RCL, PABPC1, EST, FGA, RARRES2, SLC22A, SRP14, FLJ14294, cyclin, CA2, CLDN1, FTL, FLJ10004, CYP3A5, ARHGEF12, TDO2, NDUFB2, TEGT, SPR, PCK2, MGC13114, EST, MTHFS, F2, FLJ22313, C9orf5, H | RNAs | Human | Differentially expressed between HCC and normal tissues | Diagnostic | HCC v/s normal | p < 0.01 | Tissue | 14642619 |
| 2499 | SEMA3F, DDX17, TNFAIP, PDGFRA, VIM, LAPTM5, CCND2, HLADRA, MEF2C, Staf50, SGK, REL, | RNAs | Human | Diffrenetially Expressed between recurrent and non-recurrent HCC | Prognostic | Early intrahepatic recurrence and non-recurrence HCC | p < 0.05 | Tissue | 12648972 |
| 2500 | RYBP, ATP1B3, TMC, ZNF567, GPR108, CD19, SPINK1, CDC2L6, RSRC1, METAP, GPC3, SNHG11, RY1, CRELD2, GLUL, SERPINB1, TRMT6, UNC13D, E4F1--E4F, SLC22A2, CNIH4, TK1, MAFB, PPP1CB, DNTTIP2, ARID4B, SMARCC2, PRO1386, TRIOBP, VARS, ITGA5, TERF1, PURA, TUBA1B, SNRPE, RRAGD, VWF, GLRX3, ILF2, | RNAs | Human | Upregulated in HCV related HCC than normal control (With 3-fold change) | Diagnostic | HCV related HCC v/s normal control | p < 0.01 | Tissue | 19821982 |
| 2501 | NMNAT3, OASL, TMPRSS3, MFSD7, AEBP1, UBD, S100A4, C1orf151, CRIP1, ASCC3, ZNF271, ANXA4, NMI, UBE2L6, B2 M, HLA-F, PSMB9, TAP1, PSME2, IFI16, IFI27, ARHGAP9, RABGAP1L, TNK1, DEF6, BTN3A3, RPS6KA1, CD24, PARP10, APOL3, STAT, ANKRD10, CKB, H2AFZ, PSMB9, RARRES3, RGS10, TUBB, NOL3, CD7, | RNAs | Human | Upregulated in HCV related non-HCC than normal control (With 3-fold change) | Diagnostic | HCV related non-HCC v/s normal control | p < 0.01 | Tissue | 19821982 |
| 2502 | CAPG, OCC-1, EED, RPLP0, RPLP0P2, AP1S2, RRAGD, PFDN4, CCDC104, C7orf28B, PSIP1, LPCAT1, FSCN3, RAB24, ZNF446, SEC11B, ZNF586, SCNM1, SF3A1, RUFY1, TRIM55, GOLGA4, GPATCH4, THOP1, TUBB2C, PHLDB3, FAM104A, FASTK, EIF2AK4, ZFP41, PRKRIP1, DSTN, PHIP, NUCKS1, TNRC8, CCDC132, EPRS, HIST1H4C, CDCA8, | RNAs | Human | Upregulated in HCV related HCC than HCV related non-HCC (With 3-fold change) | Diagnostic | HCV related HCC v/s HCV related non-HCC | p < 0.01 | Tissue | 19821982 |
| 2519 | Alpha-2-plasmin inhibitor, SERPINF2 | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |
| 2531 | TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, | RNAs | Human | 7 genes Downregulated i.e. CYP1A2, Human-alpha1-antitrypsin gene (S variant) complete cds, PCOLCE, CNP, DXYS155E, CLECSF14, TRIM25 and 29 get upregulated in | Diagnostic and prognostic | Single nodular HCC group v/s multicentric HCC group; associated with multicentric recurrence | p < 0.05 | Tissue | 16788756 |
| 2536 | AF147376, FLJ20084, LRP8, DKK2, AK027155, AK002039, PLSCR4, AK021998, ESDN, AKR7A2, MAP2K2, AL133075, APOL3, AK023559, GNRHR, COQ6, AF086143, FLJ14117, HUMCYT2A, D25272, M37712, KLK12, ZNF205, NM_001758, AK001102, KIAA0562, CIAO1, SRRM2, UBE1, FBXO10, AF113699, APOB, D86974, Z70704, SFRS2IP, WDFY1, | RNAs | Human | Discriminating among early-stage samples (between LGDN, HGDN and G1) | Prognostic | Dysplastic nodules of HCC v/s Edmondson grade 1 | p < 0.001 | Tissue | 16175600 |
| 2538 | ILF2, BMI1, TAF9, RFX5, SSRP1, ZNF146, SREBF2, MAFG, CHD4, NR4A1, ESR1, ZNF238, FOSB, ID1, FOS, H2AFY, SNRPB, RPS7, MRPS14, HNRPU, SNRPD2, NCL, RPS10, RPL6, SFPQ, DIM1, MARS, SFRS9, RBM3, U2AF65, SFRS1, SNRPE, SF3B4, RDBP, SNRPF, RRM1, RPL38, HNRPH1, U5-116KD, RPLP1, OXA1L, ADPRT, PRKDC, SMC4L1, H2A | RNAs | Human | Differentially Expressed in HCC Tumors than non-tumor (with fold change of 1.5) | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 15057898 |
| 2547 | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP | RNAs | Human | 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2569 | H19 and IGF2 | RNAs | Human | Upregulated in B-type HCC | Diagnostic | HBV-HCC vs HCV -HCC; associated with the progression of HCC | p < 0.05 | Tissue | 12124323 |
| 2576 | IGF2 | RNAs | Human | Upregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2584 | OAS2, ADH1A, FLJ20378, HSF2, PSME1, E2L6, UBE2L6, STAT1, LIM, FLN29, GABARAPL1, | RNAs | Human | Downregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2590 | MPV17, EST, GZMB, ITGA6, EST, CENPC1, EST, SPP1, RTF1, CYB5-M, P4HA2, DNMBP, EST, DNAJB4, PRH1, STK23, TCF2, POSTN, SPP1, WIZ, OSMR, EST, ILIA, CD44, EST, MUC6, MTHFD2, ANXA2, PCSK2, RBP1, EST, ITGA6, APRT, PDUM3, TPM2, RNASE3, OSMR, GRK1, SLC14A, FETUB, ANXA2P1, UGT2B15, EST, KIAA0703, AKAP10, AVPR | RNAs | Human | Genes associated with EHR of HCC | Prognostic | Extrahepatic recurrence (EHR) v/s Early intrahepatic recurrence (IHR) | P< 0.05 | Tissue | 17016605 |